Aquestive Therapeutics, Inc. (AQST) Total liabilities 2017–2025
Aquestive Therapeutics, Inc. (AQST) total liabilities at each fiscal year-end, per SEC filings.
$194.1MFY2025 · since FY2017: $69.6M → $194.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $194.1M | +20.1% |
| FY2024 | $161.6M | -1.4% |
| FY2023 | $163.9M | -6.7% |
| FY2022 | $175.6M | +21.9% |
| FY2021 | $144.1M | +29.4% |
| FY2020 | $111.4M | +31.7% |
| FY2019 | $84.6M | +10.2% |
| FY2018 | $76.8M | +10.3% |
| FY2017 | $69.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net incomeAQST Net marginAQST Gross profitAQST Gross marginAQST Operating incomeAQST Operating marginAQST Operating cash flowAQST Free cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Shareholders’ equityAQST overview →